Back to search resultsSummaryRMgm-1419
|
Successful modification | The parasite was generated by the genetic modification |
The mutant contains the following genetic modification(s) | Gene tagging, Introduction of a transgene |
Reference (PubMed-PMID number) |
Reference 1 (PMID number) : 26991313 |
MR4 number | |
top of page | |
Parent parasite used to introduce the genetic modification | |
Rodent Malaria Parasite | P. berghei |
Parent strain/line | P. berghei ANKA |
Name parent line/clone | P. berghei ANKA cl15cy1 |
Other information parent line | A reference wild type clone from the ANKA strain of P. berghei (PubMed: PMID: 17406255). |
top of page | |
The mutant parasite was generated by | |
Name PI/Researcher | Rijpma SR, Janse CJ, Franke-Fayard BM |
Name Group/Department | Leiden Malaria Research Group |
Name Institute | Leiden University Medical Center (LUMC) |
City | Leiden |
Country | The Netherlands |
top of page | |
Name of the mutant parasite | |
RMgm number | RMgm-1419 |
Principal name | PbMDR2::mCherry |
Alternative name | |
Standardized name | |
Is the mutant parasite cloned after genetic modification | Yes |
top of page | |
Phenotype | |
Asexual blood stage | Expression of PbMDR2::mCherry in blood stages |
Gametocyte/Gamete | Expression of PbMDR2::mCherry in gametocytes |
Fertilization and ookinete | Expression of PbMDR2::mCherry in ookinetes |
Oocyst | Weak expression of PbMDR2::mCherry in oocysts |
Sporozoite | Weak expression of PbMDR2::mCherry in sporozoites |
Liver stage | Not tested |
Additional remarks phenotype | Mutant/mutation The mutant expressing tagged MDR2 showed normal development throughout the complete life cycle indicating that the mCherry-3xMyc tag did not affect the function of MDR2. Expression of PbMDR2::mCherry was observed in blood stages and in ookinetes. Weak expression was observed in oocysts and sporozoites. In both asexual blood stages and gametocytes of Pbmdr2::mCherry fluorescence signals were detected, which is in agreement with MDR2 detection in the P. falciparum proteomes of these stages. The fluorescence signals are mainly associated with hemozoin granules (in both asexual stages, gametocytes and ookinetes), which may suggest that this protein is located on the food vacuole membrane as P. berghei trophozoites and gametocytes have many small food vacuoles. In mature schizonts these food vacuoles merge into one or two large vesicles containing hemozoin, and it is in these vesicles that we also observe fluorescent signal). In addition, fluorescence signals were found associated with the plasma lemma of blood stages, which is especially clear in merozoites of mature schizonts. Fluorescence signals were also during oocyst development. From day 10 onwards, before sporozoite formation, a highly structured fluorescence pattern is observed within the oocyst possibly associated with early sporoblast formation. In more mature oocysts, when sporozoite formation is observed, the fluorescence signal becomes more diffuse but it is only associated with the areas within the oocyst where sporozoites are present and are budding from the sporoblasts. Other mutants |
top of page | |||||||||||||||||||||||||||
Details of the target gene | |||||||||||||||||||||||||||
Gene Model of Rodent Parasite | PBANKA_1311700 | ||||||||||||||||||||||||||
Gene Model P. falciparum ortholog | PF3D7_1447900 | ||||||||||||||||||||||||||
Gene product | multidrug resistance protein 2 | ABC transporter B family member 2 | ||||||||||||||||||||||||||
Gene product: Alternative name | MDR2; ABCB2 | ||||||||||||||||||||||||||
top of page | |||||||||||||||||||||||||||
Details of the genetic modification | |||||||||||||||||||||||||||
Name of the tag | mCherry-3xMyc | ||||||||||||||||||||||||||
Details of tagging | C-terminal | ||||||||||||||||||||||||||
Additional remarks: tagging | |||||||||||||||||||||||||||
Commercial source of tag-antibodies | |||||||||||||||||||||||||||
Type of plasmid/construct | (Linear) plasmid double cross-over | ||||||||||||||||||||||||||
PlasmoGEM (Sanger) construct/vector used | No | ||||||||||||||||||||||||||
Modified PlasmoGEM construct/vector used | No | ||||||||||||||||||||||||||
Plasmid/construct map | |||||||||||||||||||||||||||
Plasmid/construct sequence | |||||||||||||||||||||||||||
Restriction sites to linearize plasmid | |||||||||||||||||||||||||||
Selectable marker used to select the mutant parasite | hdhfr/yfcu | ||||||||||||||||||||||||||
Promoter of the selectable marker | pbdhfr | ||||||||||||||||||||||||||
Selection (positive) procedure | pyrimethamine | ||||||||||||||||||||||||||
Selection (negative) procedure | No | ||||||||||||||||||||||||||
Additional remarks genetic modification | For the Pbmdr2::mCherry tagging construct, fragments at the 3’ region and the carboxy-terminal end of the coding sequence were amplified using specific primers. These fragments were cloned into the pBAT-SIL6 vector. The carboxy-terminus was cloned in frame with the mCherry-3xMyc tag. The construct to tag the mdr gene contains a GFP expression cassette. In this cassette the gfp gene is under the control of the hsp70 promoter (see for more information on the basic plasmid pBAT-SIL6 the mutant RMgm-757). | ||||||||||||||||||||||||||
Additional remarks selection procedure | |||||||||||||||||||||||||||
| |||||||||||||||||||||||||||
top of page |
top of page | |||||||||||||||||||
Type and details of transgene | |||||||||||||||||||
Is the transgene Plasmodium derived | Transgene: not Plasmodium | ||||||||||||||||||
Transgene name | GFP | ||||||||||||||||||
top of page | |||||||||||||||||||
Details of the genetic modification | |||||||||||||||||||
Inducable system used | No | ||||||||||||||||||
Additional remarks inducable system | |||||||||||||||||||
Type of plasmid/construct | (Linear) plasmid double cross-over | ||||||||||||||||||
PlasmoGEM (Sanger) construct/vector used | No | ||||||||||||||||||
Modified PlasmoGEM construct/vector used | No | ||||||||||||||||||
Plasmid/construct map | |||||||||||||||||||
Plasmid/construct sequence | |||||||||||||||||||
Restriction sites to linearize plasmid | |||||||||||||||||||
Selectable marker used to select the mutant parasite | hdhfr/yfcu | ||||||||||||||||||
Promoter of the selectable marker | pbdhfr | ||||||||||||||||||
Selection (positive) procedure | pyrimethamine | ||||||||||||||||||
Selection (negative) procedure | No | ||||||||||||||||||
Additional remarks genetic modification | For the Pbmdr2::mCherry tagging construct, fragments at the 3’ region and the carboxy-terminal end of the coding sequence were amplified using specific primers. These fragments were cloned into the pBAT-SIL6 vector. The carboxy-terminus was cloned in frame with the mCherry-3xMyc tag. The construct to tag the mdr gene contains a GFP expression cassette. In this cassette the gfp gene is under the control of the hsp70 promoter (see for more information on the basic plasmid pBAT-SIL6 the mutant RMgm-757). | ||||||||||||||||||
Additional remarks selection procedure | |||||||||||||||||||
top of page | |||||||||||||||||||
Other details transgene | |||||||||||||||||||
top of page | |||||||||||||||||||
Promoter | |||||||||||||||||||
Gene Model of Parasite | PBANKA_0711900 | ||||||||||||||||||
Gene Model P. falciparum ortholog | PF3D7_0818900 | ||||||||||||||||||
Gene product | heat shock protein 70 | ||||||||||||||||||
Gene product: Alternative name | HSP70 | ||||||||||||||||||
| |||||||||||||||||||
top of page | |||||||||||||||||||
3'-UTR | |||||||||||||||||||
Gene Model of Parasite | PBANKA_1340000 | ||||||||||||||||||
Gene product | dihydrofolate synthase/folylpolyglutamate synthase, putative | ||||||||||||||||||
Gene product: Alternative name | PbDHFS-FPGS | ||||||||||||||||||
| |||||||||||||||||||
Insertion/Replacement locus | |||||||||||||||||||
Replacement / Insertion | Replacement locus | ||||||||||||||||||
Gene Model of Parasite | PBANKA_1311700 | ||||||||||||||||||
Gene product | multidrug resistance protein 2; ABC transporter B family member 2 | ||||||||||||||||||
Gene product: Alternative name | MDR2; ABCB2 | ||||||||||||||||||
| |||||||||||||||||||
top of page |